Unlocking the Secrets of Viral Hepatitis: Join Vir Biotechnology at This Virtual Conference!

Vir Biotechnology, Inc. (NASDAQ: VIR) is proud to announce the participation of Mark Eisner, M.D., M.P.H., the Executive Vice President and Chief Medical Officer, in an engaging fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8th at 10:00 a.m. PT / 1:00 p.m. ET.

Here are some exciting highlights about Vir Biotechnology, Inc. and the upcoming event:

• Mark Eisner, a prominent figure in the company, will be sharing insights and expertise during the fireside chat, offering valuable information to attendees.
• The fireside chat will be live-streamed and accessible under the Events & Presentations section on Vir’s website at www.vir.bio. Additionally, the discussion will be archived for 30 days, allowing interested individuals to catch up on the content.
• Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company with a mission to harness the power of the immune system to create life-changing therapies for serious infectious diseases and cancer.
• Their diverse clinical-stage portfolio includes programs targeting chronic hepatitis delta, chronic hepatitis B infections, and various oncology initiatives.
• In addition to their clinical programs, Vir also boasts a robust preclinical pipeline focused on a wide array of infectious diseases and cancer-related conditions.
• The company routinely updates its website with important information for investors, maintaining transparency and engaging with stakeholders effectively.

As Vir Biotechnology, Inc. prepares for this exciting event, it continues to showcase its dedication to advancing innovative treatments and making a meaningful impact in the field of biopharmaceuticals. Stay tuned for insightful discussions and groundbreaking developments from this dynamic company.

For media inquiries, please contact Arran Attridge, Senior Vice President of Corporate Communications at [email protected]. Investors can reach out to Richard Lepke, Senior Director of Investor Relations at [email protected].